ライフサイエンスコーパス: hypersensitivity reaction

1 re, life-threatening generalized or systemic hypersensitivity reaction'.

2 One participant who received TMP-SMX had a hypersensitivity reaction.

3 entally induced peritonitis and delayed-type hypersensitivity reaction.

4 Anaphylaxis is a rapid, life-threatening hypersensitivity reaction.

5 ches for prevention of this potential deadly hypersensitivity reaction.

6 inhibition of ear swelling in a delayed-type hypersensitivity reaction.

7 Anaphylaxis is a life-threatening hypersensitivity reaction.

8 genome-wide analysis of abacavir-associated hypersensitivity reaction.

9 ion seems to be more of an antibody-mediated hypersensitivity reaction.

10 MHC variant peptide does not induce an acute hypersensitivity reaction.

11 ime period, 24 (12%) developed a carboplatin hypersensitivity reaction.

12 ges associated with a ragweed-induced type-1 hypersensitivity reaction.

13 Three of 30 patients developed a hypersensitivity reaction.

14 an indirect mechanism similar to the delayed hypersensitivity reaction.

15 ctor cells capable of causing a delayed-type hypersensitivity reaction.

16 f leukocytes at the site of the delayed-type hypersensitivity reaction.

17 S) is an acute, potentially life-threatening hypersensitivity reaction.

18 ch reduces an oxazolone-induced delayed type hypersensitivity reaction.

19 ent one of the most important causes of food hypersensitivity reaction.

20 cause of medical decision and not because of hypersensitivity reactions.

21 amount importance for the evaluation of drug hypersensitivity reactions.

22 and reportedly associated with IgE-mediated hypersensitivity reactions.

23 biotics in the UK and the commonest cause of hypersensitivity reactions.

24 ion has been well documented in delayed drug hypersensitivity reactions.

25 tis, asthma, anaphylaxis, and immediate-type hypersensitivity reactions.

26 he initiation of thrombosis and edema during hypersensitivity reactions.

27 the late elicitation phase of human type IV hypersensitivity reactions.

28 ormal T cell priming and normal delayed-type hypersensitivity reactions.

29 d other examples of IgE-associated immediate hypersensitivity reactions.

30 subjects triggers immediate non-IgE-mediated hypersensitivity reactions.

31 re needed to induce substantial delayed-type hypersensitivity reactions.

32 bind to cellular macromolecules and initiate hypersensitivity reactions.

33 ers in the vicinity of HLA-B associated with hypersensitivity reactions.

34 osemide, giving rise to possible allergic or hypersensitivity reactions.

35 be essential for development of delayed-type hypersensitivity reactions.

36 ment with sulfamethoxazole (SMX) can lead to hypersensitivity reactions.

37 ent dual-modality to interfere with allergic hypersensitivity reactions.

38 uch as metals, is frequently associated with hypersensitivity reactions.

39 agnostic and therapeutic approaches for food-hypersensitivity reactions.

40 tion episodes, cytokine release syndrome, or hypersensitivity reactions.

41 mplicated as the causative factor in certain hypersensitivity reactions.

42 IgG2a anti-hapten responses and delayed-type hypersensitivity reactions.

43 ith wild-type littermates after delayed-type hypersensitivity reactions.

44 agulants prevents cell-mediated delayed-type hypersensitivity reactions.

45 ng can be associated with nephrotoxicity and hypersensitivity reactions.

46 ducing ADRs, especially those caused by drug hypersensitivity reactions.

47 are among the most prevalent drugs inducing hypersensitivity reactions.

48 tion, and the inhibition of antigen-specific hypersensitivity reactions.

49 ure of biotherapeutic treatments and adverse hypersensitivity reactions.

50 cereals (wheat, rye and barley) can trigger hypersensitivity reactions.

51 nical setting will help to avoid severe drug hypersensitivity reactions.

52 odifying their clearance and may account for hypersensitivity reactions.

53 a higher frequency and severity of immediate hypersensitivity reactions.

54 tors (PPIs) have been known to induce type I hypersensitivity reactions.

55 ted with a chronic inflammatory response and hypersensitivity reactions.

56 ls is critical for the induction of allergic hypersensitivity reactions.

57 he mechanisms underlying IgE-mediated type I hypersensitivity reactions.

58 the dermis and potentiate local or systemic hypersensitivity reactions.

59 include information about the possibility of hypersensitivity reactions.

60 enicillin skin tests (n = 295), only 1 had a hypersensitivity reaction (0.3%; 95% CI, .06%-1.9%), and

61 thologic risk factors for LST were: 1) local hypersensitivity reaction; 2) ostial and/or bifurcation

62 s; 5.0 for nausea; 4.1 for headache; 3.1 for hypersensitivity reactions; 2.6 for urticaria; 0.2 for v

63 wing: grade 4 neutropenia (64% of patients); hypersensitivity reactions (34%, none requiring disconti

64 sea (11%), fever (8%), vomiting (8%), severe hypersensitivity reactions (8%), and diarrhea (8%).

65 pants were aged 7-16 years with an immediate hypersensitivity reaction after peanut ingestion, positi

66 Furthermore, among those with a prior hypersensitivity reaction after the receipt of a sulfona

67 Three patients developed a delayed hypersensitivity reaction after vaccination.

68 ced a case of 10-year-old girl who developed hypersensitivity reactions after eating enokitake.

69 dertook the review of all available cases of hypersensitivity reactions after placement of a drug-elu

70 od and Drug Administration (FDA) reported 50 hypersensitivity reactions after stent placement but lat

71 Acute schistosomiasis is a systemic hypersensitivity reaction against the migrating schistos

72 n mediating what are now described as type 1 hypersensitivity reactions (allergic asthma, allergic rh

73 Clinical monitoring and management of hypersensitivity reactions among patients receiving abac

74 uggestive history of a PPI-induced immediate hypersensitivity reaction and 30 control subjects were i

75 n of mice to alloantigens for a delayed-type hypersensitivity reaction and administration of neutrali

76 Kv1.3 inhibits, in vivo, both a delayed-type hypersensitivity reaction and an Ab response to an allog

77 One patient experienced a hypersensitivity reaction and developed non-neutralizing

78 -deficient mice had an enhanced delayed-type hypersensitivity reaction and increased humoral response

79 bit increased inflammation in a delayed-type hypersensitivity reaction and increased susceptibility t

80 encephalomyelitis, and had defective contact hypersensitivity reaction and local Ag-induced responses

81 ial for immunological responses that include hypersensitivity reactions and acute anaphylaxis.

82 Mast cells play a central role in type I hypersensitivity reactions and allergic disorders such a

83 Many forms of hypersensitivity reactions and allergic responses depend

84 nship between antiasparaginase antibodies or hypersensitivity reactions and event-free survival (EFS)

85 t only important effector cells in immediate hypersensitivity reactions and immune responses to patho

86 are known to have distinct roles in allergic hypersensitivity reactions and in the immune response to

87 s derived from HAART-related liver toxicity, hypersensitivity reactions and lactic acidosis are recog

88 encephalomyelitis and inhibited delayed-type hypersensitivity reactions and lymphocyte proliferation

89 unity plays a role in late phases of type IV hypersensitivity reactions and may be responding to self

90 n require a range of assays from traditional hypersensitivity reactions and microbe specific immunogl

91 and DHA suppressed antigen-specific delayed hypersensitivity reactions and mitogen-induced prolifera

92 rum IgE from patients with documented peanut hypersensitivity reactions and overlapping peptides were

93 nosis of proton pump inhibitor (PPI)-induced hypersensitivity reactions and the cross-reactivity betw

94 ng in the diagnosis of PPI-related immediate hypersensitivity reactions and the cross-reactivity patt

95 pisode of postural hypotension, one systemic hypersensitivity reaction, and grade 4 transaminitis in

96 s myocarditis, myocardial rupture, neoplasm, hypersensitivity reaction, and immune sensitization (90

97 ities encountered included thrombocytopenia, hypersensitivity reaction, and pulmonary infiltrates (fa

98 the prevalence of NSAID-induced respiratory hypersensitivity reactions, and association with chronic

99 th a reduced incidence of significant edema, hypersensitivity reactions, and dermatologic toxicities.

100 gainst intracellular pathogens, delayed-type hypersensitivity reactions, and induction of organ-speci

101 f pathologies, including autoimmune disease, hypersensitivity reactions, and sepsis.

102 se events-including metabolic complications, hypersensitivity reactions, anemia, and liver enzyme abn

103 Drug hypersensitivity reactions are an important clinical pro

104 Hypersensitivity reactions are frequent but do not preve

105 idence that some exanthematous allergic drug hypersensitivity reactions are mediated by drug-specific

106 atopic dermatitis and new insights into food hypersensitivity reactions are presented.

107 Mechanisms for DIL modeled after drug hypersensitivity reactions are unsupported experimentall

108 trations of detergents, capable of producing hypersensitivity reactions, are necessary to allow the p

109 ealed an eosinophilic infiltrate, suggesting hypersensitivity reaction as a cause of hepatotoxicity.

110 We report hypersensitivity reactions associated with fidaxomicin,

111 y experienced a severe paclitaxel-associated hypersensitivity reaction at another institution) who we

112 ffeensis, the animals developed delayed-type hypersensitivity reactions at cutaneous sites of the DNA

113 ent developed a severe paclitaxel-associated hypersensitivity reaction, but no cardiac sequela.

114 known for their harmful role in IgE-mediated hypersensitivity reactions, but their physiological role

115 ng clinically significant paclitaxel-induced hypersensitivity reactions can continue to be treated wi

116 acute lymphoblastic leukemia (ALL); however, hypersensitivity reactions can lead to suboptimal aspara

117 ties have been documented, including emesis, hypersensitivity reactions, cardiovascular events, neuro

118 is local reaction, which is likely an Arthus hypersensitivity reaction caused by high levels of antib

119 There were no reports of immediate hypersensitivity reactions caused by p55-IgG.

120 Administration of carbamazepine (CBZ) causes hypersensitivity reactions clinically characterized by s

121 te depletion, monkeys developed delayed-type hypersensitivity reactions comprised only of CD4+ T cell

122 ed arterial segments with a severe localized hypersensitivity reaction consisting predominantly of T

123 in many tissues, renin release in immediate hypersensitivity reactions could result in local angiote

124 Carboplatin hypersensitivity reactions develop in patients who have

125 However, severe delayed-type hypersensitivity reactions (DHR) induced by PPI, such as

126 Drug hypersensitivity reactions (DHRs) are a matter of great

127 sembling allergy occur, they are called drug hypersensitivity reactions (DHRs) before showing the evi

128 Drug hypersensitivity reactions (DHRs) represent growing heal

129 into the molecular basis of the delayed-type hypersensitivity reaction (DTH) provided evidence for th

130 th GM-CSF could elicit a strong delayed type hypersensitivity reaction (DTH) response, whereas peptid

131 f mice with cOVA-induced airway delayed-type hypersensitivity reaction (DTHR) but not into pulmonary

132 Hypersensitivity reactions during receipt of antibiotic

133 nd a possible cause of the high incidence of hypersensitivity reactions during the first application

134 on was observed, thus minimizing the risk of hypersensitivity reaction following vaccination with Sm-

135 t persisting as measured by the delayed-type hypersensitivity reaction for at least 7 wk.

136 a, showed diminished Ag-induced delayed type hypersensitivity reactions for up to 5 wk posttreatment.

137 ions, and differentiating possible localized hypersensitivity reactions from systemic disease are are

138 ts; only 1 of 51 subjects who did not have a hypersensitivity reaction had such antibodies (P<0.001).

139 of patients with severe immune-mediated drug hypersensitivity reactions have tendencies to develop mu

140 A high incidence of moderate to severe hypersensitivity reactions (HRs) is noted in patients wh

141 essee (TN) treated with cetuximab experience hypersensitivity reactions (HSR) at a much higher rate t

142 agement of patients with carboplatin-induced hypersensitivity reactions (HSR) has been complicated by

143 ery 3 weeks without premedication to prevent hypersensitivity reactions (HSR).

144 HIV-1 antiretroviral with treatment-limiting hypersensitivity reactions (HSRs) associated with multip

145 The immunological mechanisms driving delayed hypersensitivity reactions (HSRs) to drugs mediated by d

146 Hypersensitivity reactions (HSRs) to intravenous iron pr

147 The optimal approach to patients with hypersensitivity reactions (HSRs) to taxanes has not bee

148 t of concerns for potential infusion-related hypersensitivity reactions (HSRs), initial phase I trial

149 tibiotic-induced eosinophilia and subsequent hypersensitivity reactions (HSRs).

150 Immediate drug hypersensitivity reactions (IDHR) to moxifloxacin consti

151 Immune-mediated drug hypersensitivity reactions (IDHRs) represent a significa

152 In immediate hypersensitivity reactions, IgE effector function requir

153 sts on the diagnostic approach for immediate hypersensitivity reactions (IHR) to radiocontrast media

154 ulipid also appeared to cause a dermatologic hypersensitivity reaction in some patients.

155 In a delayed-type hypersensitivity reaction in vivo, compound 211 abolishe

156 cribes the incidence and impact of aprotinin hypersensitivity reactions in children undergoing cardio

157 are among the most commonly encountered drug hypersensitivity reactions in clinical practice.

158 formed a literature search on immediate drug hypersensitivity reactions in clonal MC disorders using

159 e innate immune signaling and promote airway hypersensitivity reactions in diseases such as asthma.

160 r 2-hydroxyethyl methacrylate (HEMA) induces hypersensitivity reactions in humans are not well-establ

161 dysfunction is a key regulator of cutaneous hypersensitivity reactions in obese mice.

162 host-related impurities, which could trigger hypersensitivity reactions in patients with rabbit aller

163 amage to the pulp cells and the induction of hypersensitivity reactions in patients.

164 hanism for the generation and persistence of hypersensitivity reactions in patients.

165 led as drug allergic as the investigation of hypersensitivity reactions in pregnancy is complex and d

166 It also blocked hypersensitivity reactions in rats carrying colon carcin

167 an T cells in vitro and reduces delayed-type hypersensitivity reactions in rats in vivo.

168 Contact hypersensitivity reactions in response to various contac

169 frequent in these patients, and delayed-type hypersensitivity reactions in the arterial walls of the

170 can trigger immediate (within minutes) local hypersensitivity reactions in the intestine followed by

171 g cells during T-cell directed, delayed-type hypersensitivity reactions in tissues, and have been rep

172 ocular nerve involvement due to leprosy, and hypersensitivity reactions in tuberculosis.

173 rated during various IgE-dependent immediate hypersensitivity reactions in vivo.

174 TIGIT-Fc inhibited delayed-type hypersensitivity reactions in wild-type but not interleu

175 Molecules that are necessary for ocular hypersensitivity reactions include the receptors CCR1 an

176 In pregnancy, acute drug-induced hypersensitivity reactions including anaphylaxis can hav

177 hanisms proposed in the pathogenesis of drug hypersensitivity reactions, including the hapten hypothe

178 C3a and C5a as potential effectors in Type 1 hypersensitivity reactions, including urticaria, rhiniti

179 y activated T cells home to the delayed type hypersensitivity reaction induced by the ova.

180 Cotreatment with CTLA4Ig also prevented hypersensitivity reactions induced by repeat dosing of B

181 Gell and Coombs classified hypersensitivity reactions into four 'types'.

182 that UVB-mediated inhibition of delayed-type hypersensitivity reactions is mediated, in part, by the

183 Currently, desensitization in delayed hypersensitivity reactions is restricted to mild, uncomp

184 in some rare instances, serious drug-induced hypersensitivity reactions, largely to the sulfapyridine

185 Safety was measured as the incidence of hypersensitivity reactions, major bleeding, and thromboc

186 Hypersensitivity reactions may prime the HPA axis to res

187 ore information on the immunopathogenesis of hypersensitivity reaction mediated by type I allergy.

188 th Schistosoma mansoni represents a cellular hypersensitivity reaction mediated by, and dependent upo

189 bodies responsible for induction of reaginic hypersensitivity reactions might have unique structures

190 Dose-limiting toxicities (DLTs) were grade 3 hypersensitivity reaction (n = 1) and neutropenic fever

191 Hypersensitivity reactions occurred in four patients.

192 No hypersensitivity reactions occurred with ABI-007 despite

193 Allergy is an acquired hypersensitivity reaction of the immune system mediated

194 ls through FcepsilonRI and trigger immediate hypersensitivity reactions on antigen encounter.

195 ng from intravesical BCG treatment include a hypersensitivity reaction or actual BCG infection of the

196 rosis factor-alpha and in vivo via a contact hypersensitivity reaction or herpes simplex virus infect

197 initiation of drug-induced blood dyscrasias, hypersensitivity reactions, or lupus-like symptoms cente

198 nges, and the inhibition of antigen-specific hypersensitivity reactions, relapsing experimental autoi

199 of patients had capillary leak syndrome and hypersensitivity reactions, respectively.

200 ed with delayed arterial healing and polymer hypersensitivity reactions resulting in chronic inflamma

201 ardized, in vivo diagnostic test for type IV hypersensitivity reactions, resulting in allergic contac

202 strated to play a key role in type II immune hypersensitivity reactions, resulting in the destruction

203 pyrophosphates alone are not responsible for hypersensitivity reactions, several modifications which

204 d activated CD4+ T cells at the delayed-type hypersensitivity reaction site.

205 and immunologic mechanisms regarding peanut hypersensitivity reactions specifically and food hyperse

206 intraocular hemorrhage, traumatic cataract, hypersensitivity reactions, stroke, myocardial infarctio

207 ntibodies are known for triggering immediate hypersensitivity reactions such as food anaphylaxis.

208 Absence of hypersensitivity reactions, superior resistance profile

209 A delayed-type hypersensitivity reaction test was administered on day 2

210 ten challenges reportedly produce a Th2-like hypersensitivity reaction (Th2-like HR).

211 is a well-recognized immune complex-mediated hypersensitivity reaction that affects all age groups, i

212 Anaphylaxis is a severe systemic hypersensitivity reaction that is rapid in onset; charac

213 Results: Two cases are reported of drug hypersensitivity reaction that were treated with cyclosp

214 various food items, with consequent risk of hypersensitivity reactions that are often severe.

215 ches carry additional risk for toxicities or hypersensitivity reactions that can result from covalent

216 the capacity to mount cutaneous delayed type hypersensitivity reactions that disappeared during the d

217 Small immune complexes cause type III hypersensitivity reactions that frequently result in tis

218 f some liposomal drugs can trigger immediate hypersensitivity reactions that include symptoms of card

219 heir immune responses resembled delayed-type hypersensitivity reactions that occurred within 24 h of

220 o be one of the major mediators of immediate hypersensitivity reactions that underlie atopic conditio

221 ES may be a cause of systemic and intrastent hypersensitivity reactions that, in some cases, have bee

222 For certain HLA allele-associated drug hypersensitivity reactions, the parent drug has been sho

223 In some HLA-associated drug hypersensitivity reactions, the presence of a risk allel

224 The remaining patient developed a hypersensitivity reaction, thus underlining the need to

225 nt adverse effects of contrast media include hypersensitivity reactions, thyroid dysfunction, and con

226 tions (N = 12), the incidence of any type of hypersensitivity reaction to a carbapenem was 3/12 (25%)

227 838), the incidence of any type of suspected hypersensitivity reaction to a carbapenem was 36/838 (4.

228 of a penicillin among patients with a prior hypersensitivity reaction to a sulfonamide antibiotic, a

229 r 1996 and July 2015 for a suspicion of drug hypersensitivity reaction to BLs, with negative ST and p

230 l skin testing did not induce a delayed type hypersensitivity reaction to cat scratch disease skin te

231 In most subjects who had a hypersensitivity reaction to cetuximab, IgE antibodies a

232 Seven patients (5%) developed a grade 3 or 4 hypersensitivity reaction to cetuximab.

233 the small intestine caused by an immunologic hypersensitivity reaction to dietary wheat gluten.

234 mon condition caused by a mast cell-mediated hypersensitivity reaction to immunoglobulin E-bound alle

235 Fifteen of the 31 patients with a hypersensitivity reaction to lansoprazole had a positive

236 ubjects who are able to mount a delayed type hypersensitivity reaction to M. tuberculosis.

237 on provide the signals necessary to induce a hypersensitivity reaction to SMX.

238 t least one episode of a clinically relevant hypersensitivity reaction to the cytotoxic drug.

239 mong 76 cetuximab-treated subjects, 25 had a hypersensitivity reaction to the drug.

240 Delayed-type hypersensitivity reaction to the injected immunogens was

241 ngs suggest that HORV is caused by a delayed hypersensitivity reaction to vancomycin.

242 ions, whereas three patients developed cross-hypersensitivity reactions to alternative structurally s

243 Hypersensitivity reactions to aprotinin have been report

244 The risk of hypersensitivity reactions to aprotinin is low in childr

245 Patients with an ACS and histories of hypersensitivity reactions to ASA, especially following

246 with stable CIHD and histories of nonsevere hypersensitivity reactions to ASA/NSAIDs, an ASA challen

247 Hypersensitivity reactions to aspirin (acetylsalicylic a

248 Posttreatment induction of delayed-type hypersensitivity reactions to autologous leukemia cells

249 ociations have been discovered for immediate hypersensitivity reactions to beta-lactams, aspirin, and

250 A high prevalence of hypersensitivity reactions to cetuximab has been reporte

251 number of patients show immediate selective hypersensitivity reactions to clavulanic acid (CLV) and

252 Patients have developed delayed-type hypersensitivity reactions to E75 postvaccination compar

253 ome of the research advances in anaphylaxis; hypersensitivity reactions to foods, drugs, and insects;

254 ome of the research advances in anaphylaxis; hypersensitivity reactions to foods, drugs, and insects;

255 ome of the research advances in anaphylaxis; hypersensitivity reactions to foods, drugs, and insects;

256 ome of the research advances in anaphylaxis; hypersensitivity reactions to foods, drugs, and insects;

257 ent mice, moreover, developed weaker contact hypersensitivity reactions to haptens applied epicutaneo

258 Nonimmediate hypersensitivity reactions to iodinated contrast media (

259 n stimulated the development of delayed-type hypersensitivity reactions to irradiated, dissociated, a

260 n stimulated the development of delayed-type hypersensitivity reactions to irradiated, dissociated, a

261 because many individuals develop cutaneous, hypersensitivity reactions to mosquito saliva after repe

262 BACKGROUND/AIM: The consensus document for hypersensitivity reactions to nonsteroidal anti-inflamma

263 A total of 370 patients with a history of hypersensitivity reactions to NSAIDs among the 1250 outp

264 In five patients (1.6%), the hypersensitivity reactions to NSAIDs did not meet the EN

265 ions and clinically useful classification of hypersensitivity reactions to NSAIDs.

266 mice failed to mount T cell and delayed type hypersensitivity reactions to OVA, suggesting that the T

267 We found that contact hypersensitivity reactions to oxazolone in mice were ass

268 l method for the diagnosis of immediate-type hypersensitivity reactions to PPIs and for the evaluatio

269 Severe hypersensitivity reactions to red meat with delay of sev

270 have identified strong linkages between drug hypersensitivity reactions to several drugs and specific

271 issued a warning of subacute thrombosis and hypersensitivity reactions to sirolimus-eluting stents (

272 ort a very low incidence of acute or delayed hypersensitivity reactions to the antivenom.

273 her malignancies, it can be anticipated that hypersensitivity reactions to the drug will become a mor

274 adults in the United States now affected by hypersensitivity reactions to various foods.

275 ular immune response (cutaneous delayed-type hypersensitivity reaction) to sheep IgG than IFN-gamma+/

276 e 3 toxicity included emesis, increased ALT, hypersensitivity reactions (two patients each), and drug

277 not associated with any manifestations of a hypersensitivity reaction upon readministration of the t

278 antigens and to respond with immediate-type hypersensitivity reactions upon subsequent exposure.

279 latex is a prerequisite to type I immediate hypersensitivity reactions (urticaria, angioedema, anaph

280 During IgE-mediated immediate hypersensitivity reactions, vascular endothelial cells p

281 n age 42.12 +/- 13.24), the leading cause of hypersensitivity reactions was metamizol (30.5%) followe

282 e-institution study of paclitaxel-associated hypersensitivity reactions, we conclude that with approp

283 998 who experienced a carboplatin-associated hypersensitivity reaction were the subjects of this eval

284 paired in homozygous mutant animals, contact hypersensitivity reactions were compromised.

285 trol of cutaneous inflammation, delayed-type hypersensitivity reactions were elicited in the ear skin

286 Thirteen (2.5%) of 552 patients experiencing hypersensitivity reactions were exposed to a BL during t

287 Delayed hypersensitivity reactions were not predictive of protec

288 No severe hypersensitivity reactions were reported despite the lac

289 teroid premedication was administered and no hypersensitivity reactions were seen.

290 smoking status, and history of NSAID-induced hypersensitivity reactions were sent to participants by

291 Incidences of vomiting and drug-hypersensitivity reactions were significantly higher in

292 it increased survival times and delayed-type hypersensitivity reactions when they are infected with C

293 her structurally different PPI without cross-hypersensitivity reactions, whereas three patients devel

294 ding of the role of CCL7 in mediating ocular hypersensitivity reactions will provide insights into ma

295 te is high, and it was produced by a delayed hypersensitivity reaction with a Th2 response.

296 xis is a severe potentially life-threatening hypersensitivity reaction with an estimated lifetime pre

297 able reliability for the absence of a severe hypersensitivity reaction with the subsequent drug infus

298 ndividuals, NSAIDs induce a wide spectrum of hypersensitivity reactions with various timing, organ ma

299 ssociated with a 6%-10% risk of developing a hypersensitivity reaction, with different phenotypes, in

300 e most frequent medicaments involved in drug hypersensitivity reactions, with NSAID-induced urticaria